Peter Wehrwein, Managing Editor

Clinicians are moving toward managing mild (Grade 1) cytokine release syndrome on an outpatient basis.

As the number of patients with multiple myeloma and lymphoma treated with CAR-T therapy increases, health systems are shifting post-infusion care from inpatient to outpatient settings. Research presented at the annual meeting of the American Society of Hematology shows the change slices costs by $19,180.

The chief medical officer of Genetix Biotherapeutics, formerly known as Bluebird bio, discusses timelines and operational challenges of the gene therapies Zynteglo for beta thalassemia and Lyfgenia for sickle cell disease.

The patient died from vent-occlusive liver disease, a well-characterized side effect of the busulfan, the myeloablative chemotherapy used to prepare the bone marrow for engraftment with the Casgevy-modified blood stem cells.

Scots ages 70-79 were 74% less likely to be hospitalized for shingles-related reasons if they were vaccinated against the disease, researchers report

Mark Nestor reveals groundbreaking insights on botulinum toxin's evolving science, enhancing its efficacy and expanding its medical applications in dermatology.

Discover how botulinum toxin injections in the glabella affect brain function, enhancing mood by altering emotional feedback from frowning.

Milliman’s Jennifer Cruz says plans are losing rebates because of steep price discounts negotiated under the Inflation Reduction Act. but that they need to be sure that renegotiation of rebate guarantees doesn’t get too broad.

Pharmacy benefit managers are approaching health plans with value-based contracts that consider lower costs on the medical benefit of the insurance, says Jennifer Cruz of Milliman.

Drugmakers are scrambling to set up direct-to-consumer programs in response to President Donald Trump’s executive orders. Should pharmacy benefit managers be worried? Are the programs good for patients?

Meet the newest member of the Managed Healthcare Executive editorial advisory board.

Milliman's Jennifer Cruz, Pharm.D., said health plans should be able to track rebates to their book of business and have strong audit rights.

Critics say it doesn’t address the misalignment and a shift from the major PBMs collecting fees instead of rebates.

In this second segment of an interview with Managed Healthcare Executive about this presentation about aesthetic dermatology at the 2025 Fall Clinical Dermatology Conference, Mark S.Nestor, M.D., Ph.D., discussed botulinum toxin injections, the effects that injections into the glalbella can have on depression and differing molecular potencies of the different brands of botulinum toxin.

In this first segment from an interview with Managed Healthcare Executive about his presentation about trends in aesthetic dermatology, the 2025 Fall Clinical Dermatology Conference in Las Vegas, Mark S. Nestor, M.D., Ph.D., talks about the shift away from hyaluronic acid to collagen stimulators, such as poly-L-lactic acid.

Determining a biologic's duration of use to treat pediatric atopic dermatitis has several factors, according to Lawrence Eichenfield, M.D., chief of pediatric and adolescent dermatology at Rady Children’s Hospital, San Diego.

Expensive, newer therapies and a lack of pediatric data are roadblocks to advancing treatment for pediatric atopic dermatitis, according to Lawrence Eichenfield, M.D., chief of pediatric and adolescent dermatology at Rady Children’s Hospital, San Diego.

The interleukin-13 inhibitors are an effective treatment for atopic dermatitis.

Lawrence Eichenfield, M.D., chief of pediatric and adolescent dermatology at Rady Children’s Hospital, San Diego, gives an overview of his session at the 2025 Fall Clinical Dermatology Conference.

Lawrence Eichenfield, M.D., chief of pediatric and adolescent dermatology at Rady Children’s Hospital, San Diego, discusses why his clinic has shifted towards earlier atopic dermatitis treatment for patients.

Results of a similar study conducted in Canada and Europe showed a prevalence of 5%.